Tate v. Commissioner of Social Security

CourtDistrict Court, N.D. Ohio
DecidedDecember 30, 2024
Docket1:24-cv-00866
StatusUnknown

This text of Tate v. Commissioner of Social Security (Tate v. Commissioner of Social Security) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Tate v. Commissioner of Social Security, (N.D. Ohio 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION

ADAM R. TATE, ) Case No. 1:24-cv-00866 ) Plaintiff, ) JUDGE CHARLES ESQUE FLEMING ) v. ) MAGISTRATE JUDGE ) REUBEN J. SHEPERD COMISSIONER OF SOCIAL SECURITY, ) ) REPORT AND RECOMMENDATION Defendant. )

I. Introduction

Plaintiff, Adam R. Tate (“Tate”), seeks judicial review of the final decision of the Commissioner of Social Security denying his application for Disability Insurance Benefits (“DIB”) under Title II of the Social Security Act. Tate raises one issue on review of the Administrative Law Judge’s (“ALJ”) decision, arguing that the ALJ’s RFC determination is unsupported by substantial evidence and is the product of legal error because the ALJ erroneously found Tate capable of performing past work as a bagger and an order picker. This matter is before me pursuant to 42 U.S.C. 405(g), 1383(c)(3) and Local Rule 72.2(b). Because the Administrative Law Judge (“ALJ”) applied proper legal standards and reached a decision supported by substantial evidence, I recommend that the Commissioner’s final decision denying Tate’s application for DIB be affirmed. II. Procedural History Having previously been found not disabled by an ALJ on May 14, 2021 (Tr. 70-87), Tate filed an application for DIB on November 2, 2021 alleging his disability began May 16, 2021. (Tr. 291-93). He alleged disability due to learning disabilities, seizures, and shaky hands syndrome. (Tr. 316). The claims were denied initially and on reconsideration. (Tr. 120, 141). He then requested a hearing before an ALJ. (Tr. 171). Tate, with representation, and a vocational expert (“VE”) testified before the ALJ on December 20, 2022. (Tr. 41-69). On November 17, 2022, the ALJ issued a written decision finding Tate not disabled. (Tr.

20-40). The Appeals Council denied his request for review on March 25, 2024, thereby rendering the ALJ’s decision the final decision of the Commissioner. (Tr. 1-7). Tate timely instituted this action on May 14, 2024. (ECF Doc. 1). III. Evidence A. Personal, Educational, and Vocational Evidence Tate was 47 years old on the date his application was filed. (Tr. 312). He required special education services while he was in school but was able to earn his high school diploma. (Tr. 317). He has past relevant work as a bagger, an order picker, and loader clerk. (Tr. 62). B. Relevant Educational and Medical Evidence Records show that on March 10, 2020, Tate presented to his cardiologist for his six

month follow up appointment with complaints of lightheadedness and dizzy spells. (Tr. 538). His past medical history was significant for syncopal episodes thought to be neurocardiogenic in nature. (Id.). An implantable loop recorder from August 2017 had previously demonstrated an episode of non-sustained ventricular tachycardia at a rate of 214 beats per minute. (Id.). At his appointment, Tate displayed no signs of ischemic heart disease or congestive heart failure. (Id.). On March 20, 2020, Tate was brought to the emergency department following a potential seizure episode. (Tr. 742). A bystander, who had performed CPR on Tate, reported that Tate was having generalized tonic-clonic activity for two unclear spans of time. (Tr. 745-746). Tate was aroused after his arrival in a confused state. (Tr. 746). He was loaded a dose of Keppra and diagnosed with generalized tonic-clonic seizure and atrial fibrillation by neurologist Tea Shergelashvilli, M.D. (Tr. 754). Tate underwent a brain MRI on April 17, 2020, which showed “. . . [s]cattered foci of subtle T2 prolongation mainly the subcortical white matter could represent minimal chronic microvascular white matter ischemic changes in the appropriate clinical

setting.” (Tr. 573). An EEG performed on May 19, 2020, was within the range of normal variation. (Tr. 622-23). A sleep-deprived EEG performed on June 24, 2020, revealed no clear-cut epileptiform activity. (Tr. 621). On August 17, 2020, Tate presented to a neurology clinic reporting shaking and twitching of his arms while he slept and headaches since he switched his dosage of Keppra. (Tr. 720). He also had a worsening tremor of his right hand. (Id.). He underwent a five-day video-EEG recording that demonstrated no abnormalities, and which provided assurance that his seizures were under good control. (Tr. 719). His diagnosis included depression, unspecified type; hypertension; GERD; and history of gastric bypass. (Id.). There is also notation of a previous diagnosis of epilepsy with a history of syncope, as well as learning disorders, tremors, and sleep

apnea. (Tr. 384). On September 10, 2020, Tate returned to his cardiologist for follow-up. (Tr. 519). The cardiologist again noted no signs or symptoms suggestive of ischemic heart disease and/or congestive heart failure, and also no worsening of symptoms of dyspnea and/or exercise tolerance. (Id.). Tate was assessed with hypertension; neurocardiogenic syncope; obstructive sleep apnea, left bundle-branch block; and non-sustained ventricular tachycardia. (Tr. 523). At a September 17, 2020 visit to his primary care doctor, exam notes indicate that his depression was showing improvement with his medications. (Tr. 487). On December 7, 2020, Tate reported he had been short-tempered and had experienced mood swings he found “bothersome.” (Tr. 586). He also reported that his tremor was interfering with his activities of daily living. (Id.). He reported on January 20, 2021. that the Keppra was causing him to be moody, so his medication was switched. (Tr. 476). Following the change in his anti-seizure medication, Tate told his physician on March 4, 2021, that he was feeling “groggy,” that he was

taking more frequent naps, and that he was having intermittent headaches. (Tr. 582). At a July 29, 2021 appointment with his neurologist, Tate complained of headaches occurring every other day with an intensity ranging from 4 to7/10. (Tr. 577). He described the headaches as sharp and pressure-like, causing light sensitivity, nausea and dizziness, and added that the headaches were worse in hot and humid conditions. (Id.). He also described experiencing “drifty, daydreaming, episodes of blanking out.” (Id.). These episodes were occurring about three times weekly for the last three months. (Id.). Examination notes from this visit indicated his essential tremor was “stable.” (Tr. 580). Tate was seen on August 2, 2021, for bilateral sensorineural hearing loss (“SNHL”) and was evaluated for hearing aids. (Tr. 395). An otoscopy showed bilateral mild to moderate SNHL

and indicated he would have difficulty hearing in most communication situations. (Tr. 401). He was deemed a candidate for aural amplification and was fitted for new hearing aids on September 22, 2021. (Tr. 405). Tate complained of feeling down and irritable on August 9, 2021, and expressed that he felt his medications were no longer effective. (Tr. 462). His prescription was adjusted, and although he felt his new medications were somewhat helpful, he still felt depressed and wanted to increase his dosage. (Tr. 456). On September 13, 2021, Tate’s neurologist referred him for video-EEG monitoring due to staring spells that he reported were occurring one to two times weekly. (Tr. 551). He reported the staring spells were brought on by watching television, but not by playing video games, which he often did all night. (Id.). He also added that he had low energy and motivation, and that he felt his Keppra had effectively treated his seizures, but he still felt depressed and anxious. (Tr. 665). The video-EEG monitoring was conducted for a period of 98 hours and 40 minutes, and was

considered normal, with no indications of epileptiform discharges, paroxysmal features, focal features, or significant interhemispheric asymmetries. (Tr. 683).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kyle v. Commissioner of Social Security
609 F.3d 847 (Sixth Circuit, 2010)
Angela M. Jones v. Commissioner of Social Security
336 F.3d 469 (Sixth Circuit, 2003)
Barbara Combs v. Commissioner of Social Security
459 F.3d 640 (Sixth Circuit, 2006)
David Bowen v. Commissioner of Social Security
478 F.3d 742 (Sixth Circuit, 2007)
Debra Rogers v. Commissioner of Social Security
486 F.3d 234 (Sixth Circuit, 2007)
Wright-Hines v. Commissioner of Social Security
597 F.3d 392 (Sixth Circuit, 2010)
Lindsley v. Commissioner of Social Security
560 F.3d 601 (Sixth Circuit, 2009)
Fleischer v. Astrue
774 F. Supp. 2d 875 (N.D. Ohio, 2011)
Carley Cunningham v. Commissioner of Social Security
360 F. App'x 606 (Sixth Circuit, 2010)
Staymate v. Commissioner of Social Security
681 F. App'x 462 (Sixth Circuit, 2017)
Biestek v. Berryhill
587 U.S. 97 (Supreme Court, 2019)
United States v. Patrick Wandahsega
924 F.3d 868 (Sixth Circuit, 2019)
Randy Berkshire v. Debra Dahl
928 F.3d 520 (Sixth Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Tate v. Commissioner of Social Security, Counsel Stack Legal Research, https://law.counselstack.com/opinion/tate-v-commissioner-of-social-security-ohnd-2024.